Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

  title={Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies},
  author={L. L. Sun and Diego Ellerman and M. Mathieu and Maria Hristopoulos and Xiaocheng Chen and Yijin Li and Xiaojie Yan and Robyn Clark and A. Reyes and E. Stefanich and E. Mai and Judy Young and C. Johnson and Mahrukh A. Huseni and X. Wang and Y. Chen and Peiyin Wang and H. Wang and N. Dybdal and Yu-Waye Chu and N. Chiorazzi and J. Scheer and T. Junttila and K. Totpal and M. S. Dennis and A. Ebens},
  journal={Science Translational Medicine},
  pages={287ra70 - 287ra70}
  • L. L. Sun, Diego Ellerman, +23 authors A. Ebens
  • Published 2015
  • Biology, Medicine
  • Science Translational Medicine
  • Anti-CD20/CD3 T cell–dependent bispecific antibodies may be useful for the treatment of B cell malignancies. Two-headed cancer therapy Immunotherapeutic approaches harness either humoral (antibody-mediated) or cellular (T cell–mediated) immunity to fight cancer. Sun et al. combine these approaches by designing a CD3/CD20 TDB (T cell–dependent bispecific), a dual-targeted antibody that recruits T cells to CD20-expressing cells. Their humanized TDB induces T cells to kill primary patient leukemia… CONTINUE READING
    An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
    • 70
    An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
    • 56
    • PDF


    Publications referenced by this paper.
    Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
    • 2,136
    • PDF
    Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma.
    • 160